Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia

Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia

The mechanistic target of rapamycin (mTOR) is a kinase whose activity is elevated in hematological malignancies. mTOR-complex-1 (mTORC1) phosphorylates numerous substrates to promote cell proliferation and survival. Eukaryotic initiation factor 4E (eIF4E)-binding proteins (4E-BPs) are mTORC1 substra...

Full description

Bibliographic Details
Main Authors: Bianca J. Lee, Sharmila Mallya, Nuntana Dinglasan, Amos Fung, Tram Nguyen, Lee-or Herzog, Joshua Thao, Edward G. Lorenzana, David Wildes, Mallika Singh, Jacqueline A. M. Smith, David A. Fruman
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Oncology
Subjects:
mTORC1
targeted (selective) treatment
4EBP1
combination therapy
Ph+ B-ALL
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.673213/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.673213/full

Similar Items